Genexine, Inc.

Equities

A095700

KR7095700001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 14/07/2024 BST			5-day change	1st Jan Change
7,120 ^KRW	+0.99%		+7.39%	-28.08%

07-04	Genexine, Inc. Appoints Jaehyun Choi as Head of R&D	CI
06-26	Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.	CI

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

July 04, 2024 at 11:22 am

Genexine, Inc. announced a merger with EPD Biotherapeutics (hereinafter referred to as 'EPD Bio') to strengthen its research workforce with expertise in PROTAC technology and enhance Genexine?s drug pipeline. Jaehyun Choi, Ph.D. founder and CEO of EPD Bio, joins Genexine as head of R&D. EPD Bio founder and CEO Dr. Jaehyun Choi, an expert in the field of targeted protein degradation technology, previously worked at Arvinas, a global leader in PROTAC (Proteolysis targeting chimera) technology and held research and scientific positions at Samsung Advanced Institute of Technology and Trillium Therapeutics. Following the merger, Dr. Choi will join Genexine as a representative director in charge of R&D along with EPD Bio's core research team.

Mr. Hong will continue as a representative director overseeing corporate development and business management.

Latest news about Genexine, Inc.

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D	07-04	CI
Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.	06-25	CI
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23/10/23	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	31/08/23	MT
Sector Update: Health Care	31/08/23	MT
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	31/08/23	MT
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	31/08/23	MT
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	31/08/23	CI
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics	28/08/23	MT
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	20/01/23	CI
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	09/01/23	CI
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Genexine to Raise $70 Million via Share Issuance	26/09/22	MT
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	08/09/22	CI
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	25/08/22	CI
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	17/08/22	CI
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	14/06/22	MT
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)	14/06/22	CI
Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer	07/06/22	CI
Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation	25/05/22	CI

Chart Genexine, Inc.

Duration

Period

More charts

Company Profile

Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENEXINE, INC.	-28.08%	214M
VERTEX PHARMACEUTICALS INCORPORATED	+21.65%	127B
REGENERON PHARMACEUTICALS, INC.	+24.51%	117B
ARGENX SE	+26.72%	27.67B
BIONTECH SE	-18.35%	20.33B
GENMAB A/S	-15.36%	16.79B
BEIGENE, LTD.	-17.65%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+13.54%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.33%	14.43B

Bio Therapeutic Drugs